Lonafarnib

氯那法尼

Report date: 2024/03/28 13:55:18
NMEFirst In Class

Base Information

Drug NameLonafarnib
Drug Alias NameSarasar洛那法尼氯那法尼Lonafarnib - Eiger BiopharmaceuticalsZOKINVY +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein farnesyltransferase inhibitors
TargetsProtein farnesyltransferase
Therapy Area/IndicationsMetastatic breast cancerCNS Embryonal TumorSolid tumours +[32] 
Global Approved IndicationsProgeria
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/11/20
Country/TerritoryBelgiumBulgariaCanada +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesOptimAIze Consulting IncSentynl Therapeutics IncEigerbio Europe Ltd +[6] 
Inactive CompaniesSchering-PloughDuke UniversityNational Cancer Institute +[6] 
Active IndicationsProgeriaSupratentorial NeoplasmsGliosarcoma +[4] 
Inactive IndicationsMetastatic breast cancerCNS Embryonal TumorSolid tumours +[28] 

Other Information

ATC CodeA16AX
Related LinksWikipediaDrugBankKEGG